Novo Nordisk has suggested that it’ll discontinue the Protaphane InnoLet human insulin (rys) 100 IU/mL injection multidose cartridge on February 1, 2025. The gadget is used significantly among the many aged as a result of it’s simple to make use of and girls with gestational diabetes mellitus.
Novo Nordisk is advising individuals to substitute Protaphane Penfill human insulin 100 IU/mL (ARTG 169635) or Humulin NPH biosynthetic human isophane insulin 100 IU/mL injection multidose cartridge (ARTG 39662).
Between now and February 1, the Therapeutic Items Administration is advising pharmacists to make use of a Severe Shortage Substitution Instrument (SSSI) to dispense the Protaphane Penfill human insulin (rys) 100 IU/mL injection multidose cartridge with out the necessity for a brand new prescription. These penfills will want a brand new insulin supply gadget and people utilizing it might want to know the way to insert cartridges and use the brand new pen safely and precisely.
Individuals dwelling with diabetes who will probably be affected by the discontinuation are suggested to ask their well being professionals about altering over to the urged replacements as quickly as attainable.
Diabetes Australia has raised considerations concerning the discontinuation, together with entry to the alternative gadget.
Whereas data for pharmacists and healthcare professionals has now been launched concerning the alternative, not all prescribers and pharmacists will see this data in a well timed method. Issues have additionally been raised about the price of the additional time or appointments that individuals dwelling with diabetes may have with their GPs, educators or endocrinologists to acquire new scripts or gadget directions.
Diabetes Australia is searching for assurances that there will probably be sufficient alternative units out there when required; that there will probably be no price to individuals dwelling with diabetes; and that the substitute units will probably be out there throughout Australia together with in regional, rural, and Aboriginal and Torres Strait Islander communities.
Diabetes Australia will proceed its advocacy on behalf of the estimated 30,000 individuals utilizing Innolet and replace the group as data turns into out there.
Additional data is offered from the Therapeutic Items Administration web site.
